Cerus Announces First U.S. Blood Center Customer Submits Biologics License Application to the FDA to Allow for Interstate Export of INTERCEPT Platelet Components
Cerus Announces Approval for the INTERCEPT Blood System from Agência Nacional de Vigilância Sanitária
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor
